SAN DIEGO, June 01, 2023 Travere Therapeutics, Inc. today announced that Company management will participate in the following upcoming conferences: William Blair 43rd Annual Growth Stock. | June 1, 2023
Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline Pegtibatinase has. | May 31, 2023
SAN DIEGO, May 11, 2023 Travere Therapeutics, Inc. today announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to six new. | May 11, 2023